Where Regenxbio Stands With Analysts
Where Regenxbio Stands With Analysts
Regenxbio在分析师中的立场
Analysts' ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
9位分析师提供的分析师对Regenxbio（纳斯达克股票代码：RGNX）在上个季度的评级从看涨到看跌不等。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.22, a high estimate of $55.00, and a low estimate of $21.00. This current average has increased by 1.25% from the previous average price target of $37.75.
分析师分析的12个月目标股价提供了见解，平均目标股价为38.22美元，最高估计为55.00美元，低估值为21.00美元。目前的平均价格较之前的平均目标价37.75美元上涨了1.25％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
In examining recent analyst actions, we gain insights into how financial experts perceive...
在研究分析师最近的行为时，...
登录免费看全文
登录/注册